We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

PromoCell Extends Portfolio to In Vitro Disease Models

PromoCell Extends Portfolio to In Vitro Disease Models content piece image
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

PromoCell, a manufacturer of human primary cells and cell culture products, now offers cell disease models covering a wide range of diseases including diabetes type 1 and 2, respiratory diseases such as COPD and asthma, as well as cardiomyopathy disease. Relevant models enable experiments under physiologic conditions and are key for developing new therapies for chronic diseases.

Large selection of donor cells with known disease status

“PromoCell now offers a large selection of donor cells with known disease status that are suitable for drug discovery and research applications,” says Daniel Spatz, CBO of PromoCell. These disease cell types can be cultured using PromoCell’s matching growth media to ensure optimal growth performance. “Our diseased cells feature the same specifications and undergo the same rigid quality control tests as their healthy counterparts from our human primary cell portfolio,” adds Irma Boercsoek, COO of PromoCell. The tests include cell factors marker characterization, growth performance and morphology.

Developing and testing potential treatment approaches

A cell disease model is an in vitro culture of cells isolated from a tissue donor with a known disease condition. By studying cell disease models, researchers gain insights in how diseases develop and this also enables them to look for new molecular targets for specific therapies. In addition, cell disease models can be used for testing potential treatment approaches.